News Flagship joins three biotechs together to form Etcelera Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.
News Ray's upscaled Series B, and other biofinancings This week's crop of private financings includes nine-figure rounds for Ray Therapeutics and Tortugas, with Serif and Alloy also in on the action.
News MSD taps Quotient for IBD drug targets in $2.2bn deal MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.
R&D Treating genetic disease at scale with tRNA, with Michelle W... Michelle Werner, Director of Alltrna, discusses her company’s approach of leveraging transfer RNA (tRNA) to shift the paradigm in genetic medicine.
News Generate's IPO gets over the line, raising $400m AI-powered drug developer Generate Biomedicine completes a $400m IPO, the largest for biotech on the Nasdaq so far this year.
News Flagship's AI-focused Generate Biomedicines files IPO Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.